High-intensity end-of-life care among Medicare beneficiaries with bladder cancer.

To quantify the proportion of patients receiving high-intensity end-of-life care, identify associated risk factors, and assess how receipt of palliative care impact end-of-life care; as the delivery of such care, and how it relates to palliative care, has not been reported in bladder cancer SUBJECTS AND METHODS: We conducted a retrospective cohort study of patients with bladder cancer who died within 1 year of diagnosis using Surveillance, Epidemiology, and End Results linked Medicare data. The primary outcome was a composite measure of high-intensity end-of-life care (>1 hospital admission, >1 ED visit, or ≥1 ICU admission within the last month of life; receipt of chemotherapy within the last 2 weeks of life; or acute care in-hospital death). Secondary outcomes included the use of such care over time and any association with the use of palliative care. A generalized linear mixed model assessed for independent determinants.

Overall, 45% of patients received high-intensity end-of-life care. This proportion decreased over time. Patients receiving high-intensity care had higher rates of comorbidities, advanced bladder cancer, and nonbladder cancer cause of death. These patients more often received palliative care but, compared to those not receiving high-intensity care, this occurred farther removed from bladder cancer diagnosis and closer to death.

Nearly half of Medicare beneficiaries with bladder cancer who die within 1 year of diagnosis receive high-intensity care at the end of life. Palliative care was seldom used and only very near the time of death.

Urologic oncology. 2021 Mar 03 [Epub ahead of print]

Lee A Hugar, Jonathan G Yabes, Pauline Filippou, Elizabeth M Wulff-Burchfield, Samia H Lopa, John Gore, Benjamin J Davies, Bruce L Jacobs

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL. Electronic address: ., Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA., Department of Urology, University of Washington School of Medicine, Seattle, WA., Medical Oncology Division and Palliative Care Division, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS.